Patient from Hell

By: Manta Cares
  • Summary

  • Are you a cancer patient? Caregiver? Survivor? Advocate? Friend? Then you've come to the right place! The Patient from Hell is a bi-weekly podcast hosted by cancer survivor, founder of Manta Cares, and self-described "patient from hell", Samira Daswani. The podcast features guests who are making the cancer experience a little easier. Each episode will educate, empower, inspire and most importantly, show you that you are not alone in your experience. Listen on Apple Podcasts, Spotify, YouTube, or wherever you listen to (or watch!) podcasts.
    671975
    Show More Show Less
Episodes
  • Episode 82: Rewriting the Story of Triple-Negative Breast Cancer with Dr. Sara Tolaney
    Jan 23 2025
    In this enlightening episode of the Patient From Hell, host Samira Daswani interviews Dr. Sara Tolaney, a leading oncologist specializing in breast cancer. They delve into the evolving landscape of triple-negative breast cancer (TNBC), exploring advancements in treatment, from targeted therapies to immunotherapy, and the challenges faced by patients in both early-stage and metastatic settings. With her characteristic warmth and expertise, Dr. Tolaney provides actionable insights for patients and caregivers, offering hope and understanding in navigating this complex diagnosis. Key Highlights: 1. A New Paradigm in Early-Stage TNBC Treatment: Dr. Tolaney explains how neoadjuvant chemotherapy combined with immunotherapy has revolutionized outcomes, achieving pathologic complete response rates above 60%. 2. Metastatic TNBC Advances: The discussion highlights the critical role of biomarker testing and the introduction of innovative therapies like antibody-drug conjugates, providing extended survival for many patients. 3. Empowering Patient Symptom Management: The episode underscores the importance of patient-reported outcomes and emerging tools like health apps to enhance self-management and real-time support for side effects. About our guest: Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Dr. Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health. Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology. Key Moments: At 8 minutes: "It used to be that if someone had a triple negative breast cancer, we would often take someone to surgery and then after surgery give them some chemotherapy to kill any stray cells that might've gotten into the bloodstream and integrate radiation as needed. But we've really changed our approach very dramatically over the last few years where we've learned that if someone has an early stage, stage two or three triple negative breast cancer, it is actually very critical that they not go to upfront surgery, but in fact get chemotherapy with immunotherapy prior to surgery." Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
    Show More Show Less
    48 mins
  • Episode 81: Finding Empowerment Through Adversity, Maimah's Triple Negative Breast Cancer Story
    Jan 8 2025

    Maimah Karmo shares her story with triple-negative breast cancer and how she founded the Tiger Lily Foundation. Maimah emphasizes the importance of self-advocacy, community support, and education in traversing healthcare challenges. She shares her experience of being dismissed by doctors due to her age and ethnicity, and how this motivated her to create an organization that empowers women of color facing similar struggles.

    Key Highlights:

    1. Trust your gut, it could save your life.

    2. Don’t do it alone, community is what will help you do what you need to do even if you’re afraid.

    3. Be the best advocate you can be for yourself, this is your life and your body – you are worth the fight.

    About our guest:

    Maimah Karmo is the Founder/CEO of the Tigerlily Foundation (Tigerlily) and an eighteen-year survivor of breast cancer. On February 28, 2006, at 4:45 p.m., Maimah was diagnosed with Stage 2 triple negative breast cancer. She had no family history and was 32-years old. While undergoing her second round of chemotherapy, she made a promise to God that if she survived, she would create an organization to educate, empower, advocate for and support young women affected by breast cancer. A first-generation immigrant from Liberia, who has experienced disparities first-hand, she is a leader in the women’s health field, creating and implementing national health initiatives for women and girls, with a goal of eliminating disparities of age, stage and color. Under Maimah’ s leadership, Tigerlily Foundation has launched national and global health initiatives focused on ending disparities, through the #InclusionPledge, partnering with global stakeholders, with a call to action to recognize health disparities as a social justice issue; and working to end disparities for black women in our lifetime. She is a global thought leader, health advocate and philanthropist, committed to justice and equity for all. Maimah also works directly with women and their families to connect the patient with better care and knowledge. through events such as the Annual Young Women’s Breast Health Day on the Hill and other philanthropic efforts and successful educational and support programs.

    You can find Maimah on Twitter, on Instagram, and on Facebook.

    Check out the Tigerlily Foundation here.

    Key Moments:

    At 6 minutes 25 seconds “I ended up finding the flower one day, the tiger lily… It's like a woman, beautiful, different layers to her, and also when people are going through treatment there's a sense of so much fear. You do lose things in a way. You may lose your petals: your hair, eyebrows, eyelashes, breasts, other parts of your body, male or female. The flower is a perennial, so in the fall, winter, the petals fall off but in the spring and summer, they blossom again. I want people who are coming to Tigerlily to feel that sense of: I'm going through this time of dormancy and things are falling off, but that means I could grow and transform into something beautiful and amazing and just badass.You could find beauty, strength and be transformed throughout the cancer journey.”

    Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

    Show More Show Less
    33 mins
  • Episode 80: SABCS 2024 Recap - Precision Medicine in Breast Cancer Care with Dr. Doug Blayney
    Dec 18 2024

    In this enlightening episode of The Patient From Hell podcast, Dr. Doug Blayney and host Samira Daswani dive deep into the key insights from the 2024 San Antonio Breast Cancer Symposium (SABCS). They explore four critical areas of breast cancer care: CDK4/6 inhibitors, antibody-drug conjugates (ADCs), de-escalation strategies for ductal carcinoma in situ (DCIS), and the emerging role of artificial intelligence in cancer diagnostics. Throughout the conversation, a central theme emerges: the increasing ability to personalize cancer treatment, considering individual patient characteristics, biological markers, treatment options, and personal goals for quality and quantity of life.

    Key Highlights:

    1. Biomarkers are becoming increasingly sophisticated, allowing for more precise and personalized treatment approaches across different breast cancer subtypes.

    2. Patient choice and individual considerations are paramount, with treatment decisions now focusing on balancing potential survival benefits against quality of life impacts.

    3. Emerging technologies like antibody-drug conjugates and artificial intelligence are revolutionizing breast cancer care by offering more nuanced, targeted diagnostic and treatment options.

    About our guest:

    Dr. Doug Blayney is an oncology physician who specializes in breast cancer and the Chief Medical Officer of Manta Cares. His research focuses on quality improvement in cancer care systems, new drug development, and patient experience improvement. At the American Society of Clinical Oncology (ASCO), he was founding Editor-in-Chief of its flagship practice journal, and as President, started the ASCO Quality Symposium and began planning for ASCO’s CancerLinq. He was a founding member of the National Comprehensive Cancer Network (NCCN) Growth Factor Guideline panel, and is a past member of the U.S. Food and Drug Administration’s Oncology Drugs Advisory Committee and the NCCN Board of Directors.

    Key Moments:

    At 38 minutes: "There's a company now that has a gene expression panel that may predict, and it looks like it does predict, whether radiation treatment after standard treatment for DCIS is beneficial. So if this predicted biomarker of benefit for radiation pans out, and I think it probably will, that means that we can deescalate or personalize whether radiation treatment and its side effects are likely to be beneficial to that patient."

    At 45 minutes: "Quality of life, can that be answered by a nine question questionnaire? Well, maybe. If you can't get out of bed, your quality of life is because something hurts or if your arm doesn't work because they're so swollen, that's one extreme... What about 15 years playing that duet? What about three? It's those kind of subtleties that we need to take into account."

    At 49 minutes:"AI can interpret mammograms. The images from a mammogram 20 years ago, there were four, top, bottom, side, side, and maybe another oblique. And now there's 60 images from a mammogram. So that means that a radiologist, a human radiologist, whether it's next door or around the world, somebody needs to look at those. AI can help."

    Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.


    Show More Show Less
    1 hr and 1 min

What listeners say about Patient from Hell

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.